1. Home
  2. YORW vs EOLS Comparison

YORW vs EOLS Comparison

Compare YORW & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo York Water Company (The)

YORW

York Water Company (The)

HOLD

Current Price

$31.34

Market Cap

472.0M

Sector

Utilities

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$4.97

Market Cap

304.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YORW
EOLS
Founded
1816
2012
Country
United States
United States
Employees
104
N/A
Industry
Water Supply
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
472.0M
304.0M
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
YORW
EOLS
Price
$31.34
$4.97
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$15.50
AVG Volume (30 Days)
76.2K
1.3M
Earning Date
06-08-2026
01-01-0001
Dividend Yield
2.91%
N/A
EPS Growth
N/A
1.23
EPS
1.39
N/A
Revenue
$77,488,000.00
$297,176,000.00
Revenue This Year
$14.53
$14.41
Revenue Next Year
$5.77
$16.96
P/E Ratio
$22.52
N/A
Revenue Growth
3.37
11.61
52 Week Low
$29.68
$4.09
52 Week High
$36.48
$13.66

Technical Indicators

Market Signals
Indicator
YORW
EOLS
Relative Strength Index (RSI) 35.57 51.88
Support Level $31.23 $4.74
Resistance Level $32.98 $6.40
Average True Range (ATR) 0.62 0.33
MACD -0.21 0.08
Stochastic Oscillator 17.49 42.09

Price Performance

Historical Comparison
YORW
EOLS

About YORW York Water Company (The)

The York Water Co is an investor-owned water utility company in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. It also owns and operates three wastewater collection systems and eleven wastewater collection and treatment systems. The company operates within its franchised territory, which covers more than 57 municipalities within four counties in south-central Pennsylvania.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: